Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management

The introduction of immunotherapy to treat recurrent/metastatic head and neck squamous cell carcinoma in 2016 has provided new valuable treatment options to many cancer patients. Pembrolizumab and nivolumab, which are classified as immune checkpoint inhibitors of programmed cell death protein 1, hav...

Descripción completa

Detalles Bibliográficos
Autor principal: Fazer, Casey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522658/
https://www.ncbi.nlm.nih.gov/pubmed/33014516
http://dx.doi.org/10.6004/jadpro.2019.10.2.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522658/
https://www.ncbi.nlm.nih.gov/pubmed/33014516
http://dx.doi.org/10.6004/jadpro.2019.10.2.12

Ejemplares similares